Non-invasive Plasma Glycomic and Metabolic Biomarkers of Post-treatment Control of HIV

Overview

Journal Nat Commun

Specialty Biology

Date 2021 Jun 30

PMID 34188039

Citations 23

Authors

Leila B Giron

Clovis S Palmer

Qin Liu

Xiangfan Yin

Emmanouil Papasavvas

Radwa Sharaf

Behzad Etemad

Mohammad Damra

Aaron R Goldman

Hsin-Yao Tang

Rowena Johnston

Karam Mounzer

Jay R Kostman

Pablo Tebas

Alan Landay

Luis J Montaner

Jeffrey M Jacobson

Jonathan Z Li

Mohamed Abdel-Mohsen

Affiliations

Soon will be listed here.

Abstract

Non-invasive biomarkers that predict HIV remission after antiretroviral therapy (ART) interruption are urgently needed. Such biomarkers can improve the safety of analytic treatment interruption (ATI) and provide mechanistic insights into the host pathways involved in post-ART HIV control. Here we report plasma glycomic and metabolic signatures of time-to-viral-rebound and probability-of-viral-remission using samples from two independent cohorts. These samples include a large number of post-treatment controllers, a rare population demonstrating sustained virologic suppression after ART-cessation. These signatures remain significant after adjusting for key demographic and clinical confounders. We also report mechanistic links between some of these biomarkers and HIV latency reactivation and/or myeloid inflammation in vitro. Finally, machine learning algorithms, based on selected sets of these biomarkers, predict time-to-viral-rebound with 74% capacity and probability-of-viral-remission with 97.5% capacity. In summary, we report non-invasive plasma biomarkers, with potential functional significance, that predict both the duration and probability of HIV remission after treatment interruption.

Citing Articles

Intestinal Microbiota and Aging in People with HIV-What We Know and What We Don't.

Islam S, Singh S, Keshavarzian A, Abdel-Mohsen M Curr HIV/AIDS Rep. 2024; 22(1):9.

PMID: 39666149 PMC: 11874070. DOI: 10.1007/s11904-024-00717-w.

The Primacy of Adipose Tissue Gene Expression and Plasma Lipidome in Cardiometabolic Disease in Persons With HIV.

Bailin S, Ma S, Perry A, Terry J, Carr J, Nair S J Infect Dis. 2024; 231(2):e407-e418.

PMID: 39657693 PMC: 11841643. DOI: 10.1093/infdis/jiae532.

Circulating immune and plasma biomarkers of time to HIV rebound in HIV controllers treated with vesatolimod.

Abdel-Mohsen M, Deeks S, Giron L, Hong K, Goldman A, Zhang L Front Immunol. 2024; 15:1405348.

PMID: 38979421 PMC: 11229794. DOI: 10.3389/fimmu.2024.1405348.

Exploring salivary metabolome alterations in people with HIV: towards early diagnostic markers.

Du F, Li R, He R, Li K, Liu J, Xiang Y Front Public Health. 2024; 12:1400332.

PMID: 38912274 PMC: 11192068. DOI: 10.3389/fpubh.2024.1400332.

Identification and verification of the role of key metabolites and metabolic pathways on ASFV replication.

Shi Z, Yang X, Shi X, Zhang D, Zhao D, Hao Y iScience. 2024; 27(4):109345.

PMID: 38500823 PMC: 10946325. DOI: 10.1016/j.isci.2024.109345.

References

Aounallah M, Dagenais-Lussier X, El-Far M, Mehraj V, Jenabian M, Routy J . Current topics in HIV pathogenesis, part 2: Inflammation drives a Warburg-like effect on the metabolism of HIV-infected subjects. Cytokine Growth Factor Rev. 2016; 28:1-10. DOI: 10.1016/j.cytogfr.2016.01.001. View

Goujard C, Girault I, Rouzioux C, Lecuroux C, Deveau C, Chaix M . HIV-1 control after transient antiretroviral treatment initiated in primary infection: role of patient characteristics and effect of therapy. Antivir Ther. 2012; 17(6):1001-9. DOI: 10.3851/IMP2273. View

Duette G, Pereyra Gerber P, Rubione J, Perez P, Landay A, Crowe S . Induction of HIF-1α by HIV-1 Infection in CD4 T Cells Promotes Viral Replication and Drives Extracellular Vesicle-Mediated Inflammation. mBio. 2018; 9(5). PMC: 6134101. DOI: 10.1128/mBio.00757-18. View

Li J, Etemad B, Ahmed H, Aga E, Bosch R, Mellors J . The size of the expressed HIV reservoir predicts timing of viral rebound after treatment interruption. AIDS. 2015; 30(3):343-53. PMC: 4840470. DOI: 10.1097/QAD.0000000000000953. View

Shehata H, Murphy A, Lee M, Gardiner C, Crowe S, Sanjabi S . Sugar or Fat?-Metabolic Requirements for Immunity to Viral Infections. Front Immunol. 2017; 8:1311. PMC: 5649203. DOI: 10.3389/fimmu.2017.01311. View

Jacobson J, Bucy R, Spritzler J, Saag M, Eron Jr J, Coombs R . Evidence that intermittent structured treatment interruption, but not immunization with ALVAC-HIV vCP1452, promotes host control of HIV replication: the results of AIDS Clinical Trials Group 5068. J Infect Dis. 2006; 194(5):623-32. DOI: 10.1086/506364. View

Williams J, Hurst J, Stohr W, Robinson N, Brown H, Fisher M . HIV-1 DNA predicts disease progression and post-treatment virological control. Elife. 2014; 3:e03821. PMC: 4199415. DOI: 10.7554/eLife.03821. View

Hurst J, Hoffmann M, Pace M, Williams J, Thornhill J, Hamlyn E . Immunological biomarkers predict HIV-1 viral rebound after treatment interruption. Nat Commun. 2015; 6:8495. PMC: 4633715. DOI: 10.1038/ncomms9495. View

Vuckovic F, Theodoratou E, Thaci K, Timofeeva M, Vojta A, Stambuk J . IgG Glycome in Colorectal Cancer. Clin Cancer Res. 2016; 22(12):3078-86. PMC: 5860729. DOI: 10.1158/1078-0432.CCR-15-1867. View

10.

Abdel-Mohsen M, Richman D, Siliciano R, Nussenzweig M, Howell B, Martinez-Picado J . Recommendations for measuring HIV reservoir size in cure-directed clinical trials. Nat Med. 2020; 26(9):1339-1350. PMC: 7703694. DOI: 10.1038/s41591-020-1022-1. View

11.

Pollack R, Jones R, Pertea M, Bruner K, Martin A, Thomas A . Defective HIV-1 Proviruses Are Expressed and Can Be Recognized by Cytotoxic T Lymphocytes, which Shape the Proviral Landscape. Cell Host Microbe. 2017; 21(4):494-506.e4. PMC: 5433942. DOI: 10.1016/j.chom.2017.03.008. View

12.

Sharaf R, Lee G, Sun X, Etemad B, Aboukhater L, Hu Z . HIV-1 proviral landscapes distinguish posttreatment controllers from noncontrollers. J Clin Invest. 2018; 128(9):4074-4085. PMC: 6118642. DOI: 10.1172/JCI120549. View

13.

Skiest D, Su Z, Havlir D, Robertson K, Coombs R, Cain P . Interruption of antiretroviral treatment in HIV-infected patients with preserved immune function is associated with a low rate of clinical progression: a prospective study by AIDS Clinical Trials Group 5170. J Infect Dis. 2007; 195(10):1426-36. DOI: 10.1086/512681. View

14.

Yang L, Wang Y, Cai H, Wang S, Shen Y, Ke C . Application of metabolomics in the diagnosis of breast cancer: a systematic review. J Cancer. 2020; 11(9):2540-2551. PMC: 7066003. DOI: 10.7150/jca.37604. View

15.

Li J, Agarwal E, Bertolini I, Seo J, Caino M, Ghosh J . The mitophagy effector FUNDC1 controls mitochondrial reprogramming and cellular plasticity in cancer cells. Sci Signal. 2020; 13(642). PMC: 7484983. DOI: 10.1126/scisignal.aaz8240. View

16.

Peng M, Yin N, Chhangawala S, Xu K, Leslie C, Li M . Aerobic glycolysis promotes T helper 1 cell differentiation through an epigenetic mechanism. Science. 2016; 354(6311):481-484. PMC: 5539971. DOI: 10.1126/science.aaf6284. View

17.

Thomann M, Reckermann K, Reusch D, Prasser J, Tejada M . Fc-galactosylation modulates antibody-dependent cellular cytotoxicity of therapeutic antibodies. Mol Immunol. 2016; 73:69-75. DOI: 10.1016/j.molimm.2016.03.002. View

18.

Keser T, Gornik I, Vuckovic F, Selak N, Pavic T, Lukic E . Increased plasma N-glycome complexity is associated with higher risk of type 2 diabetes. Diabetologia. 2017; 60(12):2352-2360. DOI: 10.1007/s00125-017-4426-9. View

19.

Rasmussen T, Tolstrup M, Brinkmann C, Olesen R, Erikstrup C, Solomon A . Panobinostat, a histone deacetylase inhibitor, for latent-virus reactivation in HIV-infected patients on suppressive antiretroviral therapy: a phase 1/2, single group, clinical trial. Lancet HIV. 2015; 1(1):e13-21. DOI: 10.1016/S2352-3018(14)70014-1. View

20.

Favre D, Mold J, Hunt P, Kanwar B, Loke P, Seu L . Tryptophan catabolism by indoleamine 2,3-dioxygenase 1 alters the balance of TH17 to regulatory T cells in HIV disease. Sci Transl Med. 2010; 2(32):32ra36. PMC: 3034445. DOI: 10.1126/scitranslmed.3000632. View